Tripterygium wilfordii Glycosides Upregulate the New Anti-Inflammatory Cytokine IL-37 through ERK1/2 and p38 MAPK Signal Pathways

• Published in: Evidence-based complementary and alternative medicine Vol. 2017; no. 2017; pp. 1 - 6
• Main Authors: Chen, Zhangquan, Zhao, Hang, He, Lingge, He, Suhui, Li, Rumeng, Wang, Sen, Deng, Xiaohong
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Anti-inflammatory drugs; Chinese medicine; Cytokines; Drug approval; Extracellular signal-regulated kinase; Glycosides; Inflammation; Inflammatory diseases; Interleukin 6; MAP kinase; Tumor necrosis factor-α; China
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2017/9148523

As a Chinese traditional patent medicine, Tripterygium wilfordii glycosides (TWG) have been approved by the China State Food and Drug Administration (Z32021007) for autoimmune and inflammatory diseases. Application of TWG leads to significant decrease of the inflammatory cytokines, such as IL-6, IL-1β, and TNF-α. However, little is known whether TWG could regulate the anti-inflammatory cytokines and what the mechanism is. Here, we found that TWG could induce the upregulation of IL-37 which is a new anti-inflammatory cytokine. Furthermore, the inhibitors of ERK1/2 and/or p38 MAPK pathways suppressed IL-37 expression induced by TWG, indicating that the two pathways took part in this process. In conclusion, TWG could upregulate the anti-inflammatory cytokine IL-37 and ERK1/2 and p38 MAPK signal pathways were involved in the upregulation of IL-37 induced by TWG. The results showed that TWG had a potent activity on promoting the expression of IL-37, a new anti-inflammatory cytokine, which help further understanding the anti-inflammatory mechanism for the clinical application of TWG in therapy of diseases.